Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ion Cristóbal, Federico Rojo, Juan Madoz-Gúrpide & Jesús García-Foncillas. (2016) Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Molecular and Cellular Biology 36:12, pages 1734-1739.
Read now
Read now
Julie M. Vose, Jonathan W. Friedberg, Edmund K. Waller, Bruce D. Cheson, Vasthala Juvvigunta, Holger Fritsch, Claude Petit, Gerd Munzert & Anas Younes. (2013) The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. Leukemia & Lymphoma 54:4, pages 708-713.
Read now
Read now
David E. Williams, Frank Loganzo, Lauren Whitney, Jenny Togias, Richard Harrison, Maya P. Singh, Leonard A. McDonald, Selvaluxmy Kathirgamanathar, Veranja Karunaratne & Raymond J. Andersen. (2011) Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity. Pharmaceutical Biology 49:3, pages 296-301.
Read now
Read now
Lin Liu, Min Zhang & Ping Zou. (2010) Polo-like kinase 1 is essential to DNA damage recovery. Leukemia & Lymphoma 51:6, pages 1079-1089.
Read now
Read now
Lin Liu, Min Zhang & Ping Zou. (2007) Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leukemia & Lymphoma 48:11, pages 2179-2183.
Read now
Read now
Luis Fayad & Anas Younes. (2006) Novel treatment strategies for aggressive non-Hodgkin’s lymphoma. Expert Opinion on Pharmacotherapy 7:6, pages 733-748.
Read now
Read now
Articles from other publishers (28)
Monika Kressin, Daniela Fietz, Sven Becker & Klaus Strebhardt. (2021) Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. Cells 10:5, pages 1176.
Crossref
Crossref
Youri Oh, Hoyong Jung, Hyejin Kim, Jihyun Baek, Joonhong Jun, Hyunwook Cho, Daseul Im & Jung-Mi Hah. (2021) Design and Synthesis of a Novel PLK1 Inhibitor Scaffold Using a Hybridized 3D-QSAR Model. International Journal of Molecular Sciences 22:8, pages 3865.
Crossref
Crossref
Xiangping Xia, Fang Cao, Xiaolu Yuan, Qiang Zhang, Wei Chen, Yunhu Yu, Hua Xiao, Chong Han & Shengtao Yao. (2019) Low expression or hypermethylation of PLK2 might predict favorable prognosis for patients with glioblastoma multiforme. PeerJ 7, pages e7974.
Crossref
Crossref
Tomonori Higuchi, Yumiko Hashida, Ayuko Taniguchi, Mikio Kamioka & Masanori Daibata. (2017) Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma. Scientific Reports 7:1.
Crossref
Crossref
Brian D. Cholewa, Mary A. Ndiaye, Wei Huang, Xiaoqi Liu & Nihal Ahmad. (2017) Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo. Cancer Letters 385, pages 179-187.
Crossref
Crossref
Stefano Ferrari & Christian Gentili. (2016) Maintaining Genome Stability in Defiance of Mitotic DNA Damage. Frontiers in Genetics 7.
Crossref
Crossref
Chetasi Talati, Elizabeth A. Griffiths, Meir Wetzler & Eunice S. Wang. (2016) Polo-like kinase inhibitors in hematologic malignancies. Critical Reviews in Oncology/Hematology 98, pages 200-210.
Crossref
Crossref
Neil D. Palmisiano & Margaret T. Kasner. (2015) Polo‐like kinase and its inhibitors: Ready for the match to start?. American Journal of Hematology 90:11, pages 1071-1076.
Crossref
Crossref
Minoru Inoue, Michio Yoshimura, Minoru Kobayashi, Akiyo Morinibu, Satoshi Itasaka, Masahiro Hiraoka & Hiroshi Harada. (2015) PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase. Scientific Reports 5:1.
Crossref
Crossref
Karineh Kazazian, Olga Brashavitskaya, Francis S. W. Zih, David Berger-Richardson, Roland S. Z. Xu, Karina Pacholczyk, Jennifer Macmillan & Carol J. Swallow. (2015) Polo-Like Kinases in Colorectal Cancer: Potential for Targeted Therapy. Current Colorectal Cancer Reports 11:4, pages 187-199.
Crossref
Crossref
RUITAO ZHANG, HUIRONG SHI, FANG REN, HUINA LIU, MINGHUI ZHANG, YOUXING DENG & XIA LI. (2015) Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis. Oncology Reports 33:3, pages 1235-1242.
Crossref
Crossref
Brian D. Cholewa, Molly C. Pellitteri-Hahn, Cameron O. Scarlett & Nihal Ahmad. (2014)
Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF
V600E
Mutant Melanoma Cells
. Journal of Proteome Research 13:11, pages 5041-5050.
Crossref
Crossref
Brian D. Cholewa, Xiaoqi Liu & Nihal Ahmad. (2013) The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?. Cancer Research 73:23, pages 6848-6855.
Crossref
Crossref
Harriet E Sandison, Suzanne Usher, Ehsan G Karimiani, Garry Ashton, Lia P Menasce, John A Radford, Kim Linton & Richard J Byers. (2013) PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome. Journal of Clinical Pathology 66:9, pages 764-767.
Crossref
Crossref
J A Pezuk, M S Brassesco, A G Morales, J C de Oliveira, R G de Paula Queiroz, H R Machado, C G CarlottiJrJr, L Neder, C A Scrideli & L G Tone. (2013) Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma. Cancer Gene Therapy 20:9, pages 499-506.
Crossref
Crossref
Barbara Valsasina, Italo Beria, Cristina Alli, Rachele Alzani, Nilla Avanzi, Dario Ballinari, Paolo Cappella, Michele Caruso, Alessia Casolaro, Antonella Ciavolella, Ulisse Cucchi, Anna De Ponti, Eduard Felder, Francesco Fiorentini, Arturo Galvani, Laura M. Gianellini, Maria L. Giorgini, Antonella Isacchi, Jaqueline Lansen, Enrico Pesenti, Simona Rizzi, Maurizio Rocchetti, Francesco Sola & Jürgen Moll. (2012) NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics 11:4, pages 1006-1016.
Crossref
Crossref
Matthew O. Duffey, Tricia J. Vos, Ruth Adams, Jennifer Alley, Justin Anthony, Cynthia Barrett, Indu Bharathan, Douglas Bowman, Nancy J. Bump, Ryan Chau, Courtney Cullis, Denise L. Driscoll, Amy Elder, Nancy Forsyth, Jonathan Frazer, Jianping Guo, Luyi Guo, Marc L. Hyer, David Janowick, Bheemashankar Kulkarni, Su-Jen Lai, Kerri Lasky, Gang Li, Jing Li, Debra Liao, Jeremy Little, Bo Peng, Mark G. Qian, Dominic J. Reynolds, Mansoureh Rezaei, Margaret Porter Scott, Todd B. Sells, Vaishali Shinde, Qiuju Judy Shi, Michael D. Sintchak, Francois Soucy, Kevin T. Sprott, Stephen G. Stroud, Michelle Nestor, Irache Visiers, Gabriel Weatherhead, Yingchun Ye & Natalie D’Amore. (2011) Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905). Journal of Medicinal Chemistry 55:1, pages 197-208.
Crossref
Crossref
Ding-pei Han, Qian-lin Zhu, Jiang-tao Cui, Pu-xiongzhi Wang, Shun Qu, Qi-feng Cao, Ya-ping Zong, Bo Feng, Min-hua Zheng & Ai-guo Lu. (2012) Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Medical Science Monitor 18:6, pages BR237-BR246.
Crossref
Crossref
Jeffrey A. Ecsedy, Mark Manfredi, Arijit Chakravarty & Natalie D’Amore. 2012. Signaling Pathways in Cancer Pathogenesis and Therapy. Signaling Pathways in Cancer Pathogenesis and Therapy
5
21
.
N. Stutz, M. Nihal & G.S. Wood. (2011) Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma. British Journal of Dermatology 164:4, pages 814-821.
Crossref
Crossref
Takayuki Ikezoe, Tamotsu Takeuchi, Jing Yang, Yoshihiro Adachi, Chie Nishioka, Mutsuo Furihata, H Phillip Koeffler & Akihito Yokoyama. (2009) Analysis of Aurora B kinase in non-Hodgkin lymphoma. Laboratory Investigation 89:12, pages 1364-1373.
Crossref
Crossref
Travis L. Schmit, Weixiong Zhong, Vijayasaradhi Setaluri, Vladimir S. Spiegelman & Nihal Ahmad. (2009) Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small-Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis in Human Melanoma Cells. Journal of Investigative Dermatology 129:12, pages 2843-2853.
Crossref
Crossref
Annelies G. Renner, Cédric Dos SantosChristian Recher, Christian Bailly, Laurent Créancier, Anna Kruczynski, Bernard Payrastre & Stéphane Manenti. (2009) Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 114:3, pages 659-662.
Crossref
Crossref
Hidenori Imai, Koichi Sugimoto, Yasushi Isobe, Makoto Sasaki, Hajime Yasuda, Kengo Takeuchi, Shinji Nakamura, Yuko Kojima, Junichi Tomomatsu & Kazuo Oshimi. (2009) Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. International Journal of Hematology 89:5, pages 673-678.
Crossref
Crossref
Zi-Li He, He Zheng, Hui Lin, Xiong-Ying Miao & De-Wu Zhong. (2009) Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients. World Journal of Gastroenterology 15:33, pages 4177.
Crossref
Crossref
Amanda Wedgwood & Anas Younes. 2008. Targeted Cancer Therapy. Targeted Cancer Therapy
157
182
.
Gabriele Buda, Valentina Maggini, Sara Galimberti, Roberto Barale, Anna Maria Rossi & Mario Petrini. (2007) Folate levels in cancer: a vitamin for a new challenge. Annals of Hematology 86:5, pages 389-389.
Crossref
Crossref
Klaus Strebhardt & Axel Ullrich. (2006) Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer 6:4, pages 321-330.
Crossref
Crossref